The systematic localization of chronic lymphocytic leukemia (CLL) B-cells in the bone marrow (BM), together with the ex vivo protective effect of stromal cells on their spontaneous apoptosis, both indicate a specific role of the BM microenvironment. In vivo, the impact of CLL cells on mesenchymal stromal cells (MSCs) remains a source of debate. Here, we quantified and expanded colony forming unit-fibroblasts (CFU-Fs) from CLL-BM under standard conditions, analyzed the expression of selected genes, and studied secretion profiles. We observed failing of CLL-BM cultures in standard conditions (45.5% vs. <0.1%), and even after adding basic fibroblast growth factor (bFGF), there were fewer CFU-F than from normal BM (1.3 vs. 40/106 cells respectively; P<0.01). Furthermore, their polygonal aspect and low proliferative capacity, together with the expression of 384 selected genes and a secreted set of molecules related to senescence-associated secretory phenotype indicated a state of senescence, further confirmed by the higher proportion of senescence-associated β-galactosidase (SA-βGAL)-positive cells and p16INK4a overexpression. In our hands, hypoxic conditions (5% O2) did not rescue CFU-Fs. Given the role of MSC in BM tissue organization, we studied hematons that are generally considered to be elementary BM units. These structures were rare or had even disappeared completely. When hematons were present, we systematically observed nodular B-CLL cell invasion only. These data confirm that the B-CLL clone has a marked impact on MSC and disrupts BM organization in vivo, raising new questions about in vivo pathophysiology.
Get full access to this article
View all access options for this article.
References
1.
PangalisGA, RoussouPA, KittasC, KokkinouS and FessasP. (1987). B-chronic lymphocytic leukemia. Prognostic implication of bone marrow histology in 120 patients experience from a single hematology unit. Cancer, 59:767–771.
2.
RozmanC, MontserratE, Rodríguez-FernándezJM, AyatsR, VallespíT, ParodyR, RíosA, PradosD, MoreyM and GomisF. (1984). Bone marrow histologic pattern—the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood, 64:642–648.
3.
MoretonP, KennedyB, LucasG, LeachM, RassamSMB, HaynesA, TigheJ, OscierD, FeganC, RawstronA and HillmenP. (2005). Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol, 23:2971–2979.
4.
ProvanD, Bartlett-PanditeL, ZwickyC, NeubergD, MaddocksA, CorradiniP, SoifferR, RitzJ, NadlerLM and GribbenJG. (1996). Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood, 88:2228–2235.
5.
RawstronAC, KennedyB, EvansPA, DaviesFE, RichardsSJ, HaynesAP, RussellNH, HaleG, MorganGJ, JackAS and HillmenP. (2001). Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood, 98:29–35.
6.
DamleRN, TemburniS, CalissanoC, YancopoulosS, BanapourT, SisonC, AllenSL, RaiKR and ChiorazziN. (2007). CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood, 110:3352–3359.
7.
ChiorazziN, RaiKR and FerrariniM. (2005). Chronic lymphocytic leukemia. N Engl J Med, 352:804–815.
8.
BurgerJA, TsukadaN, BurgerM, ZvaiflerNJ, Dell'AquilaM and KippsTJ. (2000). Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood, 96:2655–2663.
9.
CollinsRJ, VerschuerLA, HarmonBV, PrenticeRL, PopeJH and KerrJF. (1989). Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol, 71:343–350.
10.
LagneauxL, DelforgeA, De BruynC, BernierM and BronD. (1999). Adhesion to bone marrow stroma inhibits apoptosis of chronic lymphocytic leukemia cells. Leuk Lymphoma, 35:445–453.
11.
PanayiotidisP, JonesD, GaneshaguruK, ForoniL and HoffbrandAV. (1996). Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol, 92:97–103.
12.
NishioM, EndoT, TsukadaN, OhataJ, KitadaS, ReedJC, ZvaiflerNJ and KippsTJ. (2005). Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood, 106:1012–1020.
13.
TsukadaN, BurgerJA, ZvaiflerNJ and KippsTJ. (2002). Distinctive features of “nurselike”. cells that differentiate in the context of chronic lymphocytic leukemia. Blood, 99:1030–1037.
14.
DingW, NowakowskiGS, KnoxTR, BoysenJC, MaasML, SchwagerSM, WuW, WellikLE, DietzAB, et al. (2009). Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. Br J Haematol, 147:471–483.
15.
KayNE, ShanafeltTD, StregeAK, LeeYK, BoneND and Raza.A (2007). Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an “angiogenic switch.”. Leuk Res, 31:899–906.
16.
KurtovaAV, BalakrishnanK, ChenR, DingW, SchnablS, QuirogaMP, SivinaM, WierdaWG, EstrovZ, et al. (2009). Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood, 114:4441–4450.
17.
FecteauJ-F, MessmerD, ZhangS, CuiB, ChenL and KippsTJ. (2013). Impact of oxygen concentration on growth of mesenchymal stromal cells from the marrow of patients with chronic lymphocytic leukemia. Blood, 121:971–974.
18.
PontikoglouC, KastrinakiM-C, KlausM, KalpadakisC, KatonisP, AlpantakiK, PangalisGA and PapadakiHA. (2013). Study of the quantitative, functional, cytogenetic, and immunoregulatory properties of bone marrow mesenchymal stem cells in patients with B-cell chronic lymphocytic leukemia. Stem Cells Dev, 22:1329–1341.
19.
Veyrat-MassonR, Boiret-DupréN, RapatelC, DescampsS, GuillouardL, GuérinJ-J, PigeonP, BoisgardS, ChassagneJ and BergerMG. (2007). Mesenchymal content of fresh bone marrow: a proposed quality control method for cell therapy. Br J Haematol, 139:312–320.
20.
BoiretN, RapatelC, BoisgardS, CharrierS, TchirkovA, BressonC, CamilleriL, BergerJ, GuillouardL, et al. (2003). CD34+CDw90(Thy-1)+ subset colocated with mesenchymal progenitors in human normal bone marrow hematon units is enriched in colony-forming unit megakaryocytes and long-term culture-initiating cells. Exp Hematol, 31:1275–1283.
21.
ColterDC, ClassR, DiGirolamoCM and ProckopDJ. (2000). Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. Proc Natl Acad Sci U S A, 97:3213–3218.
22.
LivakKJ and SchmittgenTD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods, 25:402–408.
23.
DigirolamoCM, StokesD, ColterD, PhinneyDG, ClassR and ProckopDJ. (1999). Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Br J Haematol, 107:275–281.
24.
CoppéJ-P, PatilCK, RodierF, SunY, MuñozDP, GoldsteinJ, NelsonPS, DesprezP-Y and CampisiJ. (2008). Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol, 6:2853–2868.
25.
BinskyI, HaranM, StarletsD, GoreY, LantnerF, HarpazN, LengL, GoldenbergDM, ShvidelL, et al. (2007). IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci U S A, 104:13408–13413.
26.
BurgerJA, BurgerM and KippsTJ. (1999). Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood, 94:3658–3667.
27.
BlazsekI, LiuXH, AnjoA, QuittetP, ComissoM, Kim-TrianaB and MissetJL. (1995). The hematon, a morphogenetic functional complex in mammalian bone marrow, involves erythroblastic islands and granulocytic cobblestones. Exp Hematol, 23:309–319.
28.
BlazsekI, MissetJL, ComissoM and MathéG. (1988). Hematon: a multicellular functional unit in primary hematopoiesis. Biomed Pharmacother Bioméd, 42:661–668.
29.
PedersenIM, KitadaS, LeoniLM, ZapataJM, KarrasJG, TsukadaN, KippsTJ, ChoiYS, BennettF and ReedJC. (2002). Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood, 100:1795–1801.
30.
ShacharI, CohenS, MaromA and Becker-HermanS. (2012). Regulation of CLL survival by hypoxia-inducible factor and its target genes. FEBS Lett, 586:2906–2910.
31.
KayNE, BoneND, TschumperRC, HowellKH, GeyerSM, DewaldGW, HansonCA and JelinekDF. (2002). B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia, 16:911–919.
32.
CampisiJ and d' Adda di FagagnaF. (2007). Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol, 8:729–740.
33.
ParrinelloS, CoppeJ-P, KrtolicaA and CampisiJ. (2005). Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J Cell Sci, 118:485–496.
34.
SetheS, ScuttA and StolzingA. (2006). Aging of mesenchymal stem cells. Ageing Res Rev, 5:91–116.
35.
ShanafeltTD and KayNE. (2006). The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. Semin Oncol, 33:174–185.
36.
KawasakiBT and FarrarWL. (2008). Cancer stem cells, CD200 and immunoevasion. Trends Immunol, 29:464–468.
37.
TaiIT and TangMJ. (2008). SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother, 11:231–246.
38.
MontserratE, ViñolasN, ReverterJC and RozmanC. (1988). Natural history of chronic lymphocytic leukemia: on the progression and progression and prognosis of early clinical stages. Nouv Rev Fr Hématol, 30:359–361.
39.
RisbudMV, ShapiroIM, GuttapalliA, Di MartinoA, DanielsonKG, BeinerJM, HillibrandA, AlbertTJ, AndersonDG and VaccaroAR. (2006). Osteogenic potential of adult human stem cells of the lumbar vertebral body and the iliac crest. Spine, 31:83–89.
40.
DexterTM, SpooncerE, ToksozD and LajthaLG. (1980). The role of cells and their products in the regulation of in vitro stem cell proliferation and granulocyte development. J Supramol Struct, 13:513–524.
41.
EavesAC, CashmanJD, GabouryLA and EavesCJ. (1987). Clinical significance of long-term cultures of myeloid blood cells. Crit Rev Oncol Hematol, 7:125–138.
42.
GartnerS and KaplanHS. (1980). Long-term culture of human bone marrow cells. Proc Natl Acad Sci U S A, 77:4756–4759.
43.
WangY-K and ChenCS. (2013). Cell adhesion and mechanical stimulation in the regulation of mesenchymal stem cell differentiation. J Cell Mol Med, 17:823–832.
44.
BaraniakPR and McDevittTC. (2010). Stem cell paracrine actions and tissue regeneration. Regen Med, 5:121–143.
45.
GhiaP, CircostaP, ScielzoC, VallarioA, CamporealeA, GranzieroL and Caligaris-CappioF. (2005). Differential effects on CLL cell survival exerted by different microenvironmental elements. Curr Top Microbiol Immunol, 294:135–145.
46.
GhoshAK, SecretoCR, KnoxTR, DingW, MukhopadhyayD and KayNE. (2010). Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood, 115:1755–1764.
47.
PlanderM, UgocsaiP, SeegersS, OrsóE, ReichleA, SchmitzG, HofstädterF and BrockhoffG. (2011). Chronic lymphocytic leukemia cells induce anti-apoptotic effects of bone marrow stroma. Ann Hematol, 90:1381–1390.
48.
HaydenRE, PrattG, RobertsC, DraysonMT and BunceCM. (2012). Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches. Leuk Lymphoma, 53:537–549.
49.
HerishanuY, Pérez-GalánP, LiuD, BiancottoA, PittalugaS, VireB, GibelliniF, NjugunaN, LeeE, et al. (2011). The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood, 117:563–574.
50.
BöttcherS, RitgenM, FischerK, StilgenbauerS, BuschRM, Fingerle-RowsonG, FinkAM, BühlerA, ZenzT, et al. (2012). Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol, 30:980–988.
51.
DimitriouH, LinardakisE, MartimianakiG, StiakakiE, PerdikogianniCH, CharbordP and KalmantiM. (2008). Properties and potential of bone marrow mesenchymal stromal cells from children with hematologic diseases. Cytotherapy, 10:125–133.
52.
ZhaoZ-G, LiangY, LiK, LiW-M, LiQ-B, ChenZ-C and ZouP. (2007). Phenotypic and functional comparison of mesenchymal stem cells derived from the bone marrow of normal adults and patients with hematologic malignant diseases. Stem Cells Dev, 16:637–648.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
